Introduction
============

Thyroid cancer is the most common endocrine-related cancer that its incidence has continuously increased in the last three decades all over the world ([@B1]-[@B5]). Thyroid carcinomas are heterogeneous groups of neoplasm with typical histopathological features similar to other tumors ([@B6]).

The thyroid gland is composed of two main types of epithelial cells: the follicular cells, which convert iodine into thyroxine, also known as T~4~, and Triiodothyronine, also known as T~3~. The thyroid hormones, triiodothyronine (T~3~) and its prohormone, thyroxine (T~4~), are tyrosine-based hormones produced by the thyroid gland primarily responsible for regulation of metabolism. Another type of epithelial cells is paralfollicular or C-cells, which secrete calcitonin. Primary thyroid cancers mostly initiate from thyroid follicular cells (epithelial tumors) and develop three main pathological types of carcinomas: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and anaplastic thyroid carcinoma (ATC) contrary to medullary thyroid carcinoma (MTC) that arises from thyroid parafollicular (C) cells (7-9). Due to well differentiation and indolent tumor growth, PTC and FTC are classified as differentiated thyroid cancer (DTC). PTC consists of 85%-90% of all thyroid cancer cases, followed by FTC (5%-10%) and MTC (about 2%), while ATC accounts for a smaller amount than 2% of thyroid cancers and usually happens in the aged people ([@B10]).

The classic treatment for thyroid cancer is thyroidectomy and adjuvant radioiodine ablation that most patients can be cured, but still surgically inoperative recurrence, refractoriness to radioiodine in DTC, poorly differentiated thyroid carcinoma and ATC are unsolved. Similar to other solid cancers, thyroid cancer is commenced by genetic alterations and epigenetic changes in driver oncogenes or tumor suppressor genes ([@B11]-[@B14]). Recent advancement of molecular technologies brought a new insight to the thyroid tumors diagnosis and prognosis. The current review mainly focused on the follicular thyroid cell derived cancers genetics in order to shed light on driver genetic alterations and their importance in thyroid tumor genesis.

Molecular genetics of thyroid cancer
====================================

Thyroid cancer comes up as a result of multiple genetic and epigenetic alterations in the DNA of cancer cells. There are numerous somatic point mutations and chromosomal rearrangements in different steps of follicular cell-derived thyroid cancer ([Figure 1](#F1){ref-type="fig"}) ([@B15],[@B16]) that mainly belong to the *MAPK*signaling pathway and *RET/PTC*rearrangements ([@B17]).
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It should be kept in mind that not all the somatic abnormalities of a cancer genome are involved in initiation of the cancer since some are the consequences of carcinogenesis; hence, the terms "driver" and "passenger" mutation are made up. A driver mutation is an oncogenesis implication in cancer stem cells and is positively selected in the microenvironment of the tissue where the cancer begins and is not needed for maintenance of the final cancer (although it often is) ([@B18],[@B19]).

A passenger mutation is not selected, is not given clonal increase and therefore does not contribute to cancer development. Since somatic mutations without functional consequences often happen during cell division, passenger mutations are initiated within cancer genomes ([@B20]). One of the problematic issues is the discrimination of driver from passenger mutations. Whole-genome sequencing, however, incorporating analysis of more than 20,000 proteincoding genes and unknown numbers of functional elements in intronic and intergenic DNA, presents a greater challenge. Investigation of the biological consequences of putative driver mutations often consolidate the evidence implicating them in oncogenesis and provide insight into the subverted biological processes by which they contribute to cancer development. Thyroid cancer is a genetically simple disease with a relatively low number of mutations in each tumor. Driver mutations and gene fusions are identified in most of thyroid cancers suggesting that two main cell signaling pathways, MAPK and PI3K-AKT, are involved in the development of thyroid tumors ([@B17],[@B21]). The *MAPK/ERK*pathway, also known as the *Ras-Raf-MEK-ERK*pathway, is a transporter of a signal from a receptor on the cell surface to the nucleus (DNA) ([Figure 2](#F2){ref-type="fig"}). After binding a signaling molecule to its target receptor on the cell surface, this signaling pathway initiates and when the DNA in the nucleus expresses a protein in order to make some changes in the cell, it is terminated (22). This pathway has lots of proteins, including *MAPK*(mitogen-activated protein kinases, originally called *ERK*, extracellular signal-regulated kinases) and is connected with the cell proliferation, differentiation, migration, and senescence; and apoptosis components of the *MAPK/ ERK*pathway were discovered when they were found in cancer cells ([@B6], [@B22]-[@B24]).
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In early thyroid cancer, *MAPK*pathway is motivated by mutations in *BRAF*and *RAS*or by *RET / PTC*rearrangements. A key driver mutation upsetting *MAPK*pathway is the point mutation of *BRAF*, which makes the expression of *BRAF*^V600E^ mutant protein resulting in constitutive activation of the serine/threonine kinase ([@B26]-[@B31]). In fact, amino acid substitution at posi-, tion 600 in *BRAF*, from a Valine (V) to a glutamic acid (E) is the result of V600E mutation. This mu-i tation occurs within the activation segment of the kinase domain ([Figure 3](#F3){ref-type="fig"}). *BRAF*mutations are also frequently found in tumors with no driver mutations in *NRAS, KIT*, and other genes. *BRAF*^V600E^ mutation is found in about 45% of PTCs ([@B32], [@B33]). However, some human PTC tumors show intra-tumors heterogeneity in the *BRAF*genotype --- a minority of cells have *BRAFV600E*while the majority contain wild-type *BRAF*([@B34]).
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After *BRAF*mutations in thyroid cancer, *RAS*mutations are the most important driver genetic alteration ([@B35], [@B36]). *RAS*is in bound with GTP and when intrinsic GTPase of *RAS*hydrolyses GTP and converts *RAS*into an inactive GDP-bound state the RAS signaling is terminated ([Figure 4](#F4){ref-type="fig"}) ([@B37]). There are three isoforms of *RAS: HRAS, KRAS,*and *NRAS*, and *NRAS*is predominantly mutated in thyroid tumors, mostly involving codons 12 and 61([@B30],[@B38]). The *RAS*mutations in follicular thyroid adenoma (FTA), a supposed premalignant lesion, suggests that activated *RAS*may have a role in early follicular thyroid cell tumor genesis and higher aggressive tumor behaviors ([@B38],[@B39]). The expression of mutant *HRAS*was induced and resulted in differentiated colonies ([@B39]-[@B41]). Moreover, in the thyroid gland of transgenic mouse studies with conditional physiological expression of a *KRAS*had no transformation, but simultaneous KRAS mutant expression and *PTEN*deletion induced a rapid occurrence of aggressive FTC ([@B42]-[@B44]).
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Another main driver genetic alteration in thyroid cancer is the rearranged during transfusion (*RET*) proto-oncogene. *RET*(rearranged during transfecntion), is localized on chromosome 10 (10q11.2) and has 21 exons ([@B45]). The natural alternative splicing of the *RET*gene consequences in making three different isoforms of the protein RET; RET51, RET43, and RET9, which have 51, 43, and 9 amino acids in their C-terminal tail respectively ([@B46]). Each protein is divided into three domains: an N-terminal extra-i cellular domain with four cadherin-like repeats and a cysteine-rich region, a hydrophobic transmembrane domain and a cytoplasmic tyrosine kinase domain, which is split by an insertion of 27 amino acids ([@B47]). As a result of its capability to transform *NIH/3T3*cells by DNA rearrangement, the RET proto-oncogene was first recognized in 1985 ([@B48]). The proteins that RET encodes is a cellular tyrosine kinase transmembrane receptor that is separated into the three main domains: an N-terminal extracellular domain containing fourcadherin-like regions; a cysteine-rich region with a transmembrane domain; and a cytoplasmic domain with tyrosine kinase activity ([@B47], [@B49]-[@B51]). Four diverse ligands are described: Glial Derived Neurotrophic (*GDN*) factors, Neurturin (*NRTN*), Artimin (*ARTN*), and Persepin (*PSPN*), respectively ([@B47], [@B52], [@B53]). DNA rearrangements are a result of homologous recombination, gene conversion, and illegitimate recombination. During homologous recombination in a cell containing more than one copy of a given chromosome, one copy can combine with corresponding segments of the other. This kind of recombination is ultimately dependent upon the DNA sequence homology between the two copies. Several types of *RET/PTC*rearrangements are reported ([Table 1](#T1){ref-type="table"}) ([@B54],[@B55]). The presence of *RET/PTC*rearrangement in microcarcinoma powerfully supports the hypothesis of a driving role of this oncogene in the tumor transformation ([@B56]).

###### 

Different types of RET/PTC rearrangements in thyroid tumors according to Nikiforov YE (57)

  **Oncogene**    **Donor gene**          **Chromosomal location**
  --------------- ----------------------- --------------------------
  **RET/PTC1**    CCD6(formerly H4)       10q21
  **RET/PTC2**    PRKAR1A                 17q23
  **RET/PTC3**    NCO4 (formerly Ele 1)   10q11.2
  **RET/PTC4**    NCO4 (formerly Ele1)    10q11.2
  **RET/PTC5**    Golgas                  14q
  **RET/PTC6**    TRIM24                  7q32-34
  **RET/PTC7**    TRIM33                  1p13
  **RET/PTC8**    KTN1                    14q22.1
  **RET/PTC9**    RFG9                    18q21-22
  **ELKS-RET**    ELKS                    12p13.3
  **PCM1-RET**    PCM1                    8p21-22
  **RFP-RET**     TRIM27                  6p21
  **HOOK3-RET**   HOOK3                   8p11.21

The described *RET/PTC*prevalence in thyroid tumors varies greatly in different studies ([@B58]-[@B65]). However, this difference can be the consequence of tumor heterogeneity, ethnical and geographic variations, and dissimilar sensitivities of detection methods (66-68). *RET/PTC*rearrangements are more often in thyroid cancers after radiation exposure (50-80%) ([@B69]-[@B72]). The biological mechanisms of radiation carcinogenesis related to *RET/PTC*rearrangements are studied several times. It is observed that damage to cellular DNA is responsible for mutagenesis and carcinogenesis and those double-strand breaks are the most important event for the direct generation of gene translocations and rearrangements ([@B21], [@B73]-[@B77]). Thanks to the recent advanced next generation sequencing and whole genome sequencing, the number of candidate genetic changes in thyroid cancer has increased ([@B78]). But it is really important to discriminate between driver and passenger ones. Other genetic changes considered as passenger mutations include: *PI3K*(phosphatidylinositol-3 kinase), β-catenin (*CTNNB1*), TP53, is citrate dehydrogenase 1 (*IDH1*), anaplastic lymphoma kinase (*ALK*), and epidermal growth factor receptor (*EGFR*) ([@B79]-89). The preferential occurrences of these mutations in PDTC and ATC, which are the most aggressive thyroid cancers, indicate the fact that they may have a role in the progression and aggressiveness of thyroid cancer.

Conclusions
===========

While diverse oncogenes are involved in thyroid tumor genesis, *BRAF*and *RAS*mutations, and *RET/ PTC*rearrangements are most frequently involved as a driver changes. Notwithstanding all these observations, no strong supporting data still show a classic prognostic role for *BRAF*and *RAS*mutations, and *RET/PTC*rearrangements. But it is clear that *RET/ PTC*rearrangements are correlated with radiation exposure and are more recurrent in patients with radio induced PTC.
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